(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
Completed · Phase 2
Conditions studied: Advanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis, Systemic Mastocytosis With an Associated Hematologic Neoplasm, Mast Cell Leukemia
In brief
This is an open-label, single arm, Phase 2 study evaluating the efficacy and safety of avapritinib (BLU-285) in patients with advanced systemic mastocytosis (AdvSM), including patients with aggressive SM (ASM), SM with associated hematologic neoplasm (SM-AHN), and mast cell leukemia (MCL)
Key facts
- Study ID
- NCT03580655
- Run by
- Blueprint Medicines Corporation
- People needed
- 107
- Starts
- 2018-11-21
- Expected to finish
- 2024-12-18
- Last updated by the study team
- 2026-04-24
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Stanford Cancer Institute — Stanford, California, United States
- Rush University Medical Center — Chicago, Illinois, United States
- The University of Kansas Cancer Center — Westwood, Kansas, United States
- Dana Farber Cancer Institute — Boston, Massachusetts, United States
- University of Michigan — Ann Arbor, Michigan, United States
- Washington University School of Medicine — St Louis, Missouri, United States
- Roswell Park Comprehensive Cancer Center — Buffalo, New York, United States
- Herbert Irving Comprehensive Cancer Center — New York, New York, United States
- University of Pennsylvania, Abramson Cancer Center — Philadelphia, Pennsylvania, United States
- University of Texas, MD Anderson Cancer Center — Houston, Texas, United States
- Mays Cancer Center — San Antonio, Texas, United States
- Huntsman Cancer Institute — Salt Lake City, Utah, United States
- Medizinische Universität Wien, Universitätsklinik für Innere Medizin I, Klinische Abteilung für Hämatologie und Hämostaseologie — Vienna, Austria
- St. Michael's Hospital — Toronto, Ontario, Canada
- Odense University Hospital, Department of Haematology — Odense, Denmark
- Hôpital Necker-Enfants Malades — Paris, France
- CHU Toulouse - Hôpital Larrey — Toulouse, France
- Uniklinik RWTH Aachen, Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammzelltranslplantation — Aachen, Germany
- Universitätsklinikum Hamburg-Eppendorf, Zentrum für Onkologie — Hamburg, Germany
- Universitätsklinikum Leipzig, Medizinische Klinik und Poliklinik I - Hämatologie und Zelltherapie, lnternistische Onkologie, Hämostaseologie — Leipzig, Germany
- Universitätsmedizin Mannheim III. Medizinische Klinik — Mannheim, Germany
- Klinik und Poliklinik für Innere Medizin III, Klinikum rechts der Isar der TU München — Munich, Germany
- Azienda Ospedaliero-Universitaria Careggi, CRIMM - Centro di Ricerca ed Innovazione per le Malattie Mieloproliferative — Florence, Italy
- A.O. OO.RR. S.Giovanni di Dio e Ruggi d'Aragona, University of Salerno — Salerno, Italy
- Centro Ricerche Cliniche di Verona - Azienda Ospedaliera Universitaria Integrata di Verona — Verona, Italy
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.